Delving into the Latest Updates on Cellgram CKD with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

Allogeneic bone marrow-derived mesenchymal stem cell therapy

Target-

Mechanism

Apoptosis inhibitors, Cell replacements

Therapeutic Areas

Urogenital Diseases

Active Indication-

Inactive Indication

Chronic Kidney DiseasesErectile Dysfunction

Originator Organization

Pharmicell Co., Ltd.

Active Organization-

Inactive Organization

Pharmicell Co., Ltd.

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

This clinical trial is an open, single-center, phase 1 clinical trial to evaluate the safety of allogeneic bone marrow-derived mesenchymal stem cell injection in patients with chronic kidney disease.
The purpose is to evaluate the safety for 12 months after administration of Cellgram-CKD 3 times in 10 patients with chronic kidney disease.

Start Date24 Nov 2021

Sponsor / Collaborator

Pharmicell Co., Ltd.

NCT02344849 / CompletedPhase 1

An Open, Single-center, Phase 1 Study to Evaluate Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cell in Erectile Dysfunction.

This phase I clinical trial is designed to evaluate the safety of autologous Mesenchymal Stem Cells (MSC) injected intracavernously.

Start Date01 Jul 2015

Sponsor / Collaborator

Pharmicell Co., Ltd.

NCT01716481 / Unknown statusPhase 3IIT

Intravenous Administration of Autoserum-cultured Autologous Mesenchymal Stem Cells in Ischemic Stroke: A Single Center, Randomized, Open Label, Prospective, Phase 3 Study

The objectives of this study was to test hypothesis that ischemic stroke patients having moderate to severe persistent neurologic deficit will have better outcomes with intravenous transplantation of autologous mesenchymal stem cells (MSCs) expanded with autologous serum that is obtained at acute phase of stroke than patients receiving standard treatment.

Start Date01 Nov 2012

Sponsor / Collaborator